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ABSTRACT 
To determine whether the youngest age groups are less likely to be included in paediatric 
randomised controlled trials (PRCTs) than older children, we conducted a PubMed search 
using the keyword “randomised controlled trial” and the limit “all child: 0 – 18 years”. We 
retrieved 417 articles published in 2006 in 34 leading journals classified as general medical 
journals, paediatric medical journals, or specialist medical journals. We arbitrarily selected 
144 articles, at random. For each study, we evaluated population age characteristics (central 
tendency, range, and dispersion), study design, sample size and topic. Of the 144 studies, only 
82 were first reports of paediatric randomised controlled trials (PRCTs). Among the other 
studies, many were done in adults. Of the 82 PRCTs, only 11% included newborns and 26% 
infants; 59% included children and 39% adolescents. Using the same search strategy to 
retrieve PRCTs in the same journals in the last four months of 2009 retrieved 66 PRCTs, of 
which 17% included newborns, 24% infants, 61% children and 55% adolescents. The three 
health conditions most often reported were respiratory diseases, infectious diseases, and 
mental and behavioural disorders. In 34 leading journals, PRCTs were significantly less likely 
to include newborns and infants than older paediatric patients. Given the huge impact of 
PRCTs on paediatric health, additional efforts are needed to promote studies in newborns and 
infants, as well as studies of the impact of recent European and American regulations 
designed to encourage paediatric drug trials. 
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INTRODUCTION 
Clinical trials have led to major changes in clinical practice. In paediatrics, a well-
known example is childhood acute lymphoblastic leukaemia, in which 5-year survival has 
improved from 25% to more than 80% as a result of management changes tested in 
multicenter trials.[1] Unfortunately, the number of paediatric trials remains small.[2] At least 
50%[3-5] of drugs prescribed in children are used off-label or unlicensed, and many data on 
drug pharmacokinetics and toxicity are extrapolated from adult studies to paediatric 
populations.[3-5] Awareness of this gap in paediatric research [2, 6, 7] led to legislative and 
regulatory changes in the USA,[8] Europe,[9] and Australia,[10] with the goal of encouraging 
paediatric research. Nevertheless, many studies indicate that the number of high-quality 
randomised controlled trials (RCTs) remains lower in paediatric patients than in adults.[11-
13] For example, among the 32 RCTs investigating antiepileptic drugs for the add-on 
treatment of drug-resistant partial epilepsy, only 5 involved evaluations in both children and 
adults.[14]  
Studies that focus specifically on the paediatric population are crucial. Paediatric 
patients differ from adults in many ways, including body composition, body-surface-area to 
weight ratio, and maturation of organ systems and enzymatic pathways. Furthermore, 
considerable differences exist across the paediatric population; adolescents (12-18 years),[15, 
16] for instance, are very different from neonates (0-27 days) or infants (28 days-23 
months).[4] A case in point is the expression of drug-metabolising enzymes such as UDP 
glucuronosyltransferase, which changes with age.[4] The greatest differences in drug 
pharmacokinetics and pharmacodynamics compared to adults occur for neonates and 
infants.[4] Thus, there is an urgent need to improve the number and quality of studies 
conducted in paediatric populations,[17] particularly in neonates and infants.[12, 18]  
We hypothesised that neonates and infants were less likely to be included in paediatric 
RCTs (PRCTs) than older paediatric patients. To test this hypothesis, we reviewed a subset of 
  4/25 
PRCTs published in 34 leading journals in 2006. We evaluated study design, objective, 
sample size, and geographic location. To assess the impact of recent regulations designed to 
encourage paediatric drug trials, we retrieved the PRCTs published in the same journals 




An electronic search of MEDLINE was conducted using PubMed to identify all RCTs 
published in 2006 in 34 high-impact-factor journals. We chose the general medical journals 
(GMJs), paediatric medical journals (PMJs), and specialist medical journals (SMJs) that had 
the highest impact factors in their category, as a high impact factor is a good predictor of 
impact in the field of paediatrics and of high study quality.[19] Information on the journals, 
including impact factors, was obtained from the Institute for Scientific Information’s Journal 
Citation Reports® for 2005 (http://www.isiwebofknowledge.com/). We required an impact 
factor of 7.0 or higher for GMJs and SMJs. Since PMJs had lower impact factors, we 
arbitrarily chose a lower cut-off of 3.0 corresponding to the 90th percentile of PMJ impact 
factors listed in the 2005 Journal Citation Reports®. Furthermore, we chose journals that 
published at least ten RCTs in patients belonging to any age group, in 2006. We conducted 
our search with the keyword “randomised controlled trial”. Limits, in addition to 2006 for 
year of publication, were “Humans” and “All child: 0-18 years”. Letters, comments, and 
editorials were excluded. We identified 417 articles labelled as PRCTs including 90 (22%) in 
GMJs, 176 (42%) in PMJs, and 151 (36%) in SMJs. We arbitrarily chose to select a random 
sample of 35% of the PRCTs published in 2006, in keeping with an earlier study,[20] instead 
of a 3-month sample.[11] We used a computer-based random selection strategy stratified on 
journal category. This strategy selected 31 articles in GMJs, 60 in PMJs, and 53 in SMJs (144 
articles in all). The numbers of articles with the journal categories, names, and impact factors 
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are shown in Table 1. One of us (FA) read the titles and abstracts of the 144 articles. When 
the information in the title and abstract suggested that the study was a PRCT, the full-length 
article was read. Articles that included at least one patient aged 0 to 18 years and that 
constituted first trial reports were selected. We excluded studies that included no paediatric 
patients (even when the endpoint was assessed in a child, i.e., in newborns of pregnant 
women included in the study) and articles that supplied additional information on a previously 
reported trial. For each excluded article, we recorded the reason for exclusion. Figure 1 is the 
flow chart of the articles. We developed a standardized data collection form based on a review 
of the relevant literature then calibrated it based on 10 articles. Data were then extracted from 
the selected articles to the form by one of us (FA), who is a certified paediatrician. Among the 
data extracted from each article were the characteristics of the population, with special 
attention to age, for which we recorded the central tendency (mean or median), range, and 
dispersion (standard deviation or interquartile range). We also recorded the number of 
patients, male-to-female ratio, topic of the study (determined using a list published by the 10th 
International Statistical Classification of Diseases and Related Health Problems,[21] continent 
where the study was done, type of intervention (treatment, diagnosis, or prevention), and 
whether age-related subgroup analyses were performed. We classified the studies based on the 
age groups included, using the following definitions: neonates, 0-27 days; infants, 28 days-23 
months; children, 2-11 years; and adolescents, 12-18 years [15, 16]. Preterm babies were 
defined as babies born before 37 weeks of gestation [15, 16]. If the mean or median age, or at 
least part of the age range, was contained within the interval defining an age group, the study 
was classified as including at least that age group. Incomplete age data were handled as 
follows. When only one end of the age range was known, we used this value and the interval 
separating it from the mean to identify the age group. When some of the included patients 
were younger than 18 years, but the minimum age was missing, and when the maximum and 
mean ages were either missing or greater than 18 years, the study was classified as a PRCT in 
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an unspecified age group. We did not evaluate whether the treatments studied in the older age 
groups were relevant to the younger age groups. We tested interobserver variability of our 
data extraction method by having one of us (FK), who was blinded to the results of the initial 
data extraction, independently extract data from a random sample of 35% of the 144 articles. 
We also performed a MEDLINE search using the same strategy to identify PRCTs published 
in the same 34 journals between 1st September 2009 and 31st December 2009. We chose a 4-
month period to obtain about one-third of PRCTs published in 2009, as we included 35% of 
PRCTs published in during 2006 in the same journals. To maximize the likelihood of 
detecting an impact of the recent regulations, we chose the latest possible time period, that is, 




Qualitative variables were described as numbers (percentages) and quantitative variables 
as medians (range and interquartile range). Our assessment of interobserver variability 
showed perfect agreement for the identification of PRCTs (Kappa =1) and substantial 
agreement for the main extracted items (Kappa =0.70; 95% confidence interval [95%CI], 
0.62-0.79). We used Fisher’s test to compare age-group distributions in PRCTs published in 
2006 and 2009. 
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RESULTS 
 
Selected Articles  
Of the 144 articles, 82 were found to be PRCTs. The 62 other articles were done in 
adults or were not first reports of RCTs (Figure 1); therefore, they were excluded from the 
analysis. 
Study characteristics 
Reported age characteristics in the 82 articles are shown in Table 2. A single paediatric 
age group was included in 46 studies, two paediatric age groups in 29 studies, and three 
paediatric age groups in 4 studies. Of the 13 studies that included both adults and paediatric 
patients, three did not provide sufficient data to determine the age group of the paediatric 
participants. Among the 44 PRCTs published in 2006 that included either patients from at 
least two paediatric age-groups or both adults and children, 6 reported age-related subgroup 
analyses. The distribution of age groups is shown in Table 3 for the 2006 sample of PRCTs 
and in Table 4 for the 2009 sample. Far fewer studies were done in neonates and infants than 
in older paediatric patients. There was no statistically significant difference in age-group 
distribution between 2006 and 2009 (p=0.77). Sample size ranged from 22 to 69,274, with a 
median of 196. The male-to-female ratio was available for 67 studies and ranged from 0.1 to 
0.91 with a median of 0.53. Topics of the PRCTs published in 2006 and 2009 are listed in 
Table 5. The most widely studied topics were infectious diseases (15 on vaccines), respiratory 
diseases (including 19 on asthma), and mental and behavioural disorders. Only 2 studies dealt 
with surgical conditions. In 2006, trials on asthma and vaccines contributed 29% of all trials. 
Most of the 12 trials on rare diseases included both paediatric patients and adults. Of the 66 
therapeutic trials, 53 evaluated drugs, most of which had already been used in paediatric 
patients or adults. Among the remaining trials, 14 assessed preventive or educational 
interventions and 2 assessed diagnostic tools. Of the 82 trials, 41 (50%) were done in North 
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America, 27 (33%) in the European Union, 12 (15%) in Asia, 5 (6%) in Africa, 5 (6%) in 
Australasia, and 4 (5%) in Latin America. The total exceeds 82 because seven studies 
involved at least two regions. In four articles, the geographic region where the study was done 
was not clearly described. For 58 of the 66 PRCTs published in the last four months of 2009, 





PRCTs published in 34 leading journals in 2006 and during the last four months of 2009 
were less likely to include neonates and infants than children or adolescents. A review of 
articles published in 2005 in six leading general and specialist journals showed that studies 
performed in adults were significantly more likely than paediatric studies to be RCTs, 
systematic reviews, or studies of therapeutic interventions.[11] Compared to studies in adults, 
studies in paediatric patients are fewer, less well designed, and less well reported.[12] In 
addition to this previously described paucity of high-quality paediatric studies, we found that 
few paediatric studies focused on the youngest patients. Drug pharmacokinetics and 
pharmacodynamics differ significantly between adults and paediatric patients and across 
paediatric age groups.[4, 22] Drugs that are effective and safe in adults or older paediatric 
patients may be neither in neonates and infants. For instance, the administration in the 1950s 
of chloramphenicol to neonates in a total daily dosage based on experience with adults caused 
the potentially fatal side effect known as grey baby syndrome related to liver enzyme 
immaturity.[23] However, many drugs are not tested in paediatric patients, who must 
therefore be given drugs off-label. In a multicenter study of 344,094  inpatients in tertiary 
paediatric hospitals in the United States, at least one drug was used off-label in 78.7% of the 
overall study population.[5] The younger the child, the greater the difference with adults. 
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Both the nature and the dosage of drugs must be adapted to the specific characteristics of each 
paediatric age group. About 20% of drug prescriptions written for paediatric patients are 
written for infants,[24] and the use of unlicensed drugs is highest among children younger 
than 1 year.[25] Among drugs used in neonates, up to 90% may be given off-label.[26] The 
prevalences of the various health conditions in each age group were estimated based on 
several indicators. In a study of annual outpatient visit rates between 1993-1995 in the USA, 
rates were highest among patients younger than 1 year of age (800 visits per 100 children 
versus 200 visits per 100 children aged 5 to 14 years).[27] The main diagnoses in this study 
were middle ear infections (especially in patients younger than 1 year), injury (especially in 
patients older than 5 years), asthma (with similar rates in infants, preschoolers, and school-age 
children), and attention deficit disorders.[27] In 2006 in the USA, 155 000 children were 
admitted for asthma and contributed 5.6% of all admitted children; there were also 593 000 
emergency room visits of children for asthma, contributing 2.3% of all paediatric emergency 
room visits.[28] The numbers of admissions and visits were highest among the youngest 
patients and decreased with advancing age, although the prevalence of asthma was higher in 
school-age children and adolescents.[28] A hospital discharge survey performed in the USA 
in 2005 showed that 45% of neonates had at least one illness or risk-related diagnosis.[29] 
Common diagnoses were perinatal jaundice (20%), respiratory conditions (11%), disorders 
related to prematurity (8%), and congenital anomalies (8%).[29]. The prevalence of chronic 
conditions was studied over 6 years in the USA in children aged 2 years at inclusion. 
Prevalences were 2% to 3.6% for asthma, 11.9% to 13.3% for obesity, 1% to 4.7% for mental 
and behavioural disorders, and 3.9% to 5.7% for other physical conditions.[30] Fewer data are 
available on the worldwide scale. A study of major causes of death in children younger than 5 
years[31] showed that diarrhoea and pneumonia each contributed 17% of deaths, followed by 
other infections (12%), severe neonatal infections (11%), prematurity (11%), birth asphyxia 
and trauma (8%), malaria (7%), measles (4%), injuries (4%), and nutritional deficiencies. 
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Thus, chronic health conditions predominate in older children, whereas acute and severe 
illnesses are more common in the youngest patients. Therefore, although neonates and infants 
contribute a smaller proportion of the paediatric population than do older age groups, their 
specific characteristics require a large amount of research attention. Clearly, there is an urgent 
need for high-quality studies in neonates and infants. Nevertheless, despite a few initiatives to 
promote research in neonates,[32] most paediatric studies are done in children and 
adolescents, as shown by a study of 253 trials conducted to obtain paediatric exclusivity 
extensions.[33] Drugs studied in these trials are mainly used in older children and adolescents 
for conditions such as hypertension, systemic autoimmune disorders, and gastrointestinal 
disorders.[33] We identified important deficiencies in the reporting of age characteristics of 
populations included in PRCTs. In 17% of the PRCTs published in 2006, at least one major 
age characteristic was missing. Furthermore, 40% trials included more than one paediatric age 
group. In this situation, detailed information on the number of participants in each age group 
is crucial. Inadequate information on age characteristics limits the external validity and 
therefore the usefulness of PRCTs.[12] Finally, of the 13 trials that included both adults and 
paediatric patients, 12 did not specify the number of each. Only 6 PRCTs involved age-related 
subgroup analyses. In many PRCTs, sample sizes were too small for valid subgroup analyses. 
The three health conditions most often studied in PRCTs were respiratory diseases, infectious 
diseases, and mental and behavioural disorders, in keeping with earlier data.[33] Asthma and 
vaccines contributed 29% of the trials in our study. Studies of asthma were done chiefly in 
children and studies of vaccines in infants. Although surgery is a high-cost intervention, only 
2 trials investigated surgical treatments. Similarly, there were few studies of diagnostic 
procedures. We excluded 62 of the 144 initially selected articles. Many of the excluded 
articles reported studies in adults, although they were associated with paediatric keywords 
(e.g., “adolescent”). Differences in age-group definitions further complicate the identification 
of PRCTs on Medline. For example, the age range for adolescence is 12 to 18 years according 
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to the ICH definition used by the US Department of Health[16] and European Medicines 
Agency[15] and 13 to 18 years according to the Medical Subject Headings (MeSH, United 
States National Library of Medicine (http://www.nlm.nih.gov/mesh/meshhome.html) used for 
PubMed search limits. There is clearly a need for standardizing age-group definitions.[12] 
Reporting of age characteristics in PRCTs also needs to be improved, to ensure easy 
identification of paediatric age groups included in trials. Nevertheless, we were able to 
determine the age groups in most of the trials selected for our study. We excluded RCTs in 
pregnant women. Although RCTs performed during pregnancy are numerous and often 
relevant to paediatrics, for instance in the field of HIV infection, they are not influenced by 
new legislation about paediatric research. Low publication rates of PRCTs done to obtain 
exclusivity extensions have been found.[33] PRCTs of interventions whose use is well 
established in adults may be unlikely to be accepted for publication by peer-reviewed 
journals. Publication bias may occur when the studies are conducted in narrow fields or with 
small effect sizes or when they fail to show efficacy of the study intervention.[34] These 
sources of publication bias are often present in paediatric trials, especially in the youngest 
age-groups. Thus, our focus on published RCTs is a limitation of our study. 
Because we focused on paediatric journals having high impact factors, most 
subspecialty paediatric journals were excluded. PRCTs may have been published in these 
excluded journals. However, only data published in peer-reviewed journals are likely to have 
a major impact on clinical practice.[11, 33] Labelling issues constitute only the most visible 
part of the far-reaching deficiencies that characterize paediatric clinical research. Because the 
rules applying to drug use are more restrictive than in other fields (e.g., there is no equivalent 
of labelling in surgery), the imbalance in labelling between adults and children and across 
paediatric age groups is more easily recognizable, compared to other problems affecting 
paediatric research. Labelling requires published studies, and labelling inadequacies constitute 
a marker for the more extensive problems that affect paediatric clinical research. 
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Only 13 of the 148 trials identified in our study were done in preterm babies. Survival is 
increasing among extremely immature newborns, in whom drug handling and toxicity differ 
markedly from those in older patients. High-quality studies in immature babies are needed to 
determine the risk/benefit profile of drugs and the mechanisms of drug toxicity.[35] 
Limitations on blood sampling are among the specific challenges raised by 
pharmacodynamic, pharmacokinetic, and pharmacogenetic studies in preterm babies.[36] 
However, methods have been devised to circumvent this problem.[37]  
The need for special attention to paediatric drugs was recognized in the 1990s. The Food 
and Drug Administration Modernization Act of 1997 (FDAMA) required the FDA to specify 
which drugs must carry paediatric labelling. The Best Pharmaceuticals for Children Act 
(BPCA) passed in 2002 encourages more studies in children and promotes the development of 
treatments for children; it offers extended exclusivity to pharmaceutical companies that 
perform studies in children. The Pediatric Research Equity Act (PREA) of 2003 allows the 
FDA to require paediatric drug trials sponsored by pharmaceutical companies when such 
studies are not performed despite incentives and publicly funded mechanisms.[38] The Food 
and Drug Administration Amendments Act of 2007 (FDAAA) extends applicability of the 
BPCA and PREA authority to 2012. The paediatric exclusivity program in the USA provided 
paediatric data for 59 drugs between 2002 and 2004, and the cost of the PRCTs was offset by 
the net returns from the additional 6 months of exclusive marketing rights.[39] This program 
seems effective for high-cost diseases that also exist in adults, such as asthma,[40, 41] but 
may be less useful for conditions not seen in adults. Other types of program are needed to 
encourage research in neonates and infants. Since 2006 (the year chosen for our first study), 
new laws and regulations (FDAAA, EMEA paediatric initiative, and FP-7) have been enacted 
to promote clinical research in paediatrics. However, our evaluation of PRCTs published in 
late 2009 found no changes in age-group distribution compared to 2006. However, only 12% 
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of the 2009 PRCTs had inclusion periods that started in or after 2007. Thus, the time interval 
may have been too short to detect an effect of the new regulations.  
 
CONCLUSION 
Paediatric health issues vary across age group: infectious diseases and the need for 
immunizations are crucially important in the youngest children, whereas mental and 
behavioural disorders chiefly affect older children. Newborns and infants were less often 
included in RCTs published in 2006 and in the 4 last months of 2009 than older paediatric 
patients, although their specific characteristics entail a need for specific studies. Additional 
efforts are needed to promote research in neonates and infants. Further studies designed to 
evaluate the impact of recent regulations may provide insight into the best means of 
encouraging PRCTs conducted in the youngest age groups and published in high impact 
factor journals. Furthermore, age group definitions must be standardized and improvements 
made in the reporting of age characteristics in PRCTs.[42] 
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FIGURE LEGEND 
Figure 1. Flow of articles in the literature search 
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Table 1. Number of articles published in 2006 retrieved in Medline using PubMed and 
identified as paediatric randomised controlled trials 
Name of journal n of PRCTs 
New England Journal of Medicine 27 
Lancet 21 
Journal of the American Medical Association 7 
Annals of Internal Medicine 2 
BMJ 25 
Archives of Internal Medicine 8 
Sub-Total for GMJs (n=6) 90 
  
Pediatrics 79 
Journal of the American Academy of Child and 
Adolescent Psychiatry 
30 
The Journal of Pediatrics 28 
Archives of Pediatrics & Adolescent Medicine 22 
The Pediatric Infectious Disease Journal 17 
Sub-Total for PMJs (n=5) 176 
  
Archives of General Psychiatry 6 
Gastroenterology 6 
Journal of Clinical Oncology 16 
Circulation 3 
Lancet Neurology 4 
Blood 19 
Lancet Infectious Disease 0 
Hepatology 2 
Lancet Oncology 2 
Journal of the American College of Cardiology 5 
American Journal of Respiratory and Critical Care 
Medicine 
6 
The American Journal of Psychiatry 18 
Diabetes 2 
Diabetes care 11 
Gut 3 
The Journal of Allergy and Clinical Immunology 31 
Annals of Neurology 1 
Brain 1 
Arthritis and Rheumatism 5 
European Heart Journal 3 
Journal of the American Society of Nephrology 3 
Arteriosclerosis, Thrombosis, and Vascular Biology 1 
Annals of the Rheumatic Diseases 2 
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Table 2. Availability of age characteristics in 82 paediatric randomised controlled trials, by 
journal category 
 








Mean 72 (88%) 12 (67%) 43 (93%) 17 (94%) 
Dispersion (standard deviation 
or interquartile range) 52 (63%) 9 (50%) 31 (67%) 12 (67%) 
Full age range (min - max) 61 (74%) 11 (61%) 40 (87%) 10 (56%) 
Mean and either full age  
range or dispersion 68 (83%) 11 (61%) 40 (87%) 17 (94%) 
Dispersion and mean  
and full age range 37 (45%) 4 (22%) 28 (61%) 5 (28%) 
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Table 3. Description of paediatric age groups included in 82 paediatric randomised controlled 
trials, by journal category in 2006. 
 








Preterm (born before 37 weeks) 6 (7%) 3 (17%) 3 (7%) 0 
Newborn (full-term, aged 0 to 28 
days) 9 (11%) 2 (11%) 7 (15%) 0 
Infant (28 days to 2 years) 21 (26%) 6 (33%) 11 (24%) 4 (22%) 
Child (2 years to 12 years) 48 (59%) 9 (50%) 29 (63%) 10 (56%) 
Adolescent (12 years to 18 years) 32 (39%) 1 (6%) 19 (41%) 12 (67%) 
Adults and children 13 (16%) 1 (6%) 1 (2%) 11 (61%) 
*Since several PRCTs included patients in several age groups, the total is greater than 82 
(100%). 
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Table 4. Description of paediatric age groups included in 66 paediatric randomised controlled 
trials, by journal category in the last four months of 2009. 








Preterm (born before 37 weeks) 7 (11%) 1 (5%) 6 (19%) 0 
Newborn (full-term, aged 0 to 28 
days) 11 (17%) 4 (19%) 7 (22%) 0 
Infant (28 days to 2 years) 16 (24%) 7 (33%) 7 (22%) 2 (15%) 
Child (2 years to 12 years) 40 (61%) 12 (57%) 20 (63%) 8 (62%) 
Adolescent (12 years to 18 years) 36 (55%) 12 (57%) 14 (44%) 10 (77%) 
*Since several PRCTs included patients in several age groups, the total is greater than 82 
(100%). 
 
  24/25 
Table 5. Topics of the PRCTs 




Infectious disease 24 21 
Diseases of respiratory system 20 6 
Mental and behavioural disorders 10 8 
Injury, poisoning, and other external insults 9 2 
Diseases of circulatory system 8 4 
Diseases of the digestive system 7 8 
Endocrine, nutritional, and metabolic diseases 5 9 
Conditions originating in the perinatal period 5 4 
Haematological malignancies 4 6 
Diseases of the skin and subcutaneous tissue 3 1 
Pregnancy, childbirth, and puerperium 2 1 
Diseases of the nervous system 1 6 
Diseases of the genitourinary system 1 2 
Other 1 0 
* Several PRCTs concern multiple topics and the total is therefore greater than 82. 
§ Several PRCTs concern multiple topics and the total is therefore greater than 66. 
 
 






SMJs: n=53  
 
=> 144 full-length articles assessed for eligibility 
417 articles  
published in 2006 
 identified as PRCTs in MEDLINE 
using PubMed 
GMJs: n=90 
PMJs: n=176  











13 adult RCTs   
14 Exclusions 
3 adult RCTs   
5 previously 
reported RCTs  
5 not RCTs 
1 other 
35 Exclusions 
20 adult RCTs   
10 previously 
reported RCTs  
5 not RCTs 
 
82 articles studied 
 
Random sample of 35% in 
each journal category 
